Search results
Marinus reports mixed results in status epilepticus trial By Investing.com
Investing.com· 1 hour agoMarinus (NASDAQ:MRNS) Pharmaceuticals, Inc. (NASDAQ:MRNS) has announced topline results from the...
J&J's phase 2 Sjögren's data support FcRn strategy in the autoimmune disorder
FierceBiotech· 2 hours agoThe unveiling of Johnson & Johnson’s full data from the phase 2 trial of nipocalimab in Sjögren's disease (SjD) suggest that both the Big Pharma and its competitor argenx ...
Grifols prepares for late-stage plans with plasma-derived medicines in 2024
Pharmaceutical Technology via Yahoo Finance· 37 minutes agoGrifols plans to release Phase III results of its long-term albumin treatment designed to increase...
CARsgen’s CAR T MM therapy shows early signs of efficacy in Phase I trial
Clinical Trials Arena via Yahoo Finance· 2 hours agoShanghai based-biotech company CARsgen Therapeutics has announced that its CAR T cell candidate...
Lilly’s Phase II results in Alzheimer’s disease have most experts saying donanemab is done
Clinical Trials Arena via Yahoo Finance· 9 hours agoEli Lilly’s donanemab for early symptomatic Alzheimer’s disease (AD) has most experts dubious of the...
Equinor and GRTgaz to develop CO₂ transport system in France
Offshore Technology via Yahoo Finance· 45 minutes agoThe initial phase will have a capacity of three to 5.5 million tonnes (mt) of CO₂ per year, with...
Soup-To-Nuts Podcast: If social media is not the ‘be all end all’ in marketing – what is?
Food Navigator USA· 3 hours agoA two-phase qualitative and quantitative study examining how 7,000 consumers discover, evaluate and...
Why 90% Of Aerovate Therapeutics' Value Just Went Up In Smoke
Investor's Business Daily· 33 minutes agoAerovate Therapeutics said Monday its experimental blood pressure medicine failed in Phase 2...
ALS pipeline suffers a major hit as Biogen’s Tofersen fails phase iii trial
Clinical Trials Arena via Yahoo Finance· 10 hours agoBiogen's Tofersen did not meet its efficacy results in the Phase III VALOR study for ALS, which...
Takeda flunks pivotal epilepsy tests but mulls path to market for Ovid-partnered prospect
FierceBiotech· 2 hours agoTakeda’s late-phase epilepsy program has failed a key test, chalking up misses on the primary endpoints in pivotal trials in two indications. The drug candidate, the cholesterol ...